Soleil Securities Reiterates a 'Buy' on Cephalon (CEPH); Near-Term Catalysts Likely to Aid Shares

March 26, 2010 7:36 AM EDT Send to a Friend
Get Alerts CEPH Hot Sheet
Price: $81.49 --0%

Rating Summary:
    1 Buy, 14 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade CEPH Now!
Join SI Premium – FREE
Soleil Securities reiterates a 'Buy' on Cephalon (Nasdaq: CEPH), price target $92.

Soleil analyst says, "Building on the recent strength in CEPH shares, we are awaiting positive news on two different fronts this coming Monday, March 29, 2010, that are likely to continue to drive shares higher. We are awaiting 1) a positive decision by FDA on Nuvigil for jet-lag, and 2) positive Treanda sales data for February 2010."

To see all the upgrades/downgrades on shares of CEPH, visit our Analyst Ratings page.

Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in four core therapeutic areas: central nervous system (CNS), pain, oncology and inflammatory disease.

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Soleil Securities

Add Your Comment